Navigation Links
ExonHit is Honoured by the "Innovation Trophy" From The National Institute of Industrial Property (INPI)

PARIS, December 4 /PRNewswire-FirstCall/ -- ExonHit Therapeutics S.A. (Alternext: ALEHT), a drug and diagnostic discovery company, is pleased to announce today that it has been honoured by the INPI (National Institute of Industrial Property) during the last edition of its "Trophee de l'Innovation" (Innovation Trophy).

"Since its inception, ExonHit consistently made efforts to maintain and to protect the value of its intellectual property and in particular from its international patents. The discovery activities has allowed the Company to reach a leading intellectual property position, in the field of alternative splicing technologies as well as for drug candidates and innovative diagnostic solutions. This wide position is a true asset which results today in a portfolio of 204 international patents", declared Frederique Schlumberger, general counsel of ExonHit Therapeutics.

Loic Maurel, Chairman of the Executive Board of ExonHit Therapeutics, added : "I'm very proud to receive from the INPI this award in the name of all our teams of researchers who work for the company on a daily basis. This distinction is all the more symbolic in that it occurs at a key time of our development. Actually, in a few months, ExonHit is preparing the release of a first range of blood diagnostic tests for Alzheimer's disease in which all our collaborators have provided strong support to us. This future success would have never happened without a dedicated attention to defending our intellectual property. These patents are critical in our industry. They precede industrial successes and the creation of value of biotechnology companies like ExonHit ".

A ceremony took place this day in Paris, in the presence of Benoit Battistelli, General manager of the INPI, and Marc Antoine Jamet, President of the Union of the Manufacturers.

About ExonHit Therapeutics

ExonHit Therapeutics is the world's leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases.

ExonHit has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays, SpliceArrayTM family of products, that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit has a major collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers.

In parallel, ExonHit is developing its own therapeutic pipeline in the field of neurodegenerative diseases and cancer. The Company has advanced drug candidates into clinical trials and is evaluating several promising pre-clinical compounds. ExonHit also has a strategic partnership with Allergan, to discover and develop new therapeutics in the areas of pain, neurological diseases and ophthalmology. This collaboration provides on-going research funding to ExonHit.

Founded in 1997, ExonHit is headquartered in Paris, France and has a U.S. facility in Gaithersburg, Maryland. The Company is listed on Alternext of Euronext Paris (ticker: ALEHT; ISIN: FR0004054427) since November 17, 2005.

This press release includes only summary information and does not purport to be comprehensive. The projections, forecast and estimates of ExonHit Therapeutics which may be contained herein are for illustrative purposes only and are based on management's current views and assumptions. Such projections, forecast and estimates involve known and unknown risks and uncertainties, as described at Section 4.2 "Facteurs de risque" (Risk Factors) of the Document de Base available on ExonHit Therapeutics' website (, that may cause actual results, performance or events to differ materially from those anticipated in the summary information.

In addition, ExonHit Therapeutics, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.

Finally, this press release may be drafted in the French and English languages. In an event of differences between the texts, the French language version shall prevail.

SOURCE ExonHit Therapeutics SA
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ExonHit Launches Mouse Genome SpliceArray(TM) for use in Human Disease Modeling Studies
2. Loic Maurel Joins Exonhit Therapeutics to Become CEO
3. ExonHit Launches Rat Genome SpliceArray(TM) Products to Expand High Resolution Gene Expression Profiling for use in Disease Modeling and Toxicogenomics
4. Frederic Desdouits Appointed Member of the Supervisory Board of ExonHit Therapeutics
5. ExonHit Appoints a New Management Board
6. ExonHit Therapeutics - 2007 Financial Results
7. ExonHit Builds A New Organisation
8. ExonHit and bioMerieux Amend Their Strategic Partnership
9. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
10. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
11. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
Post Your Comments:
(Date:6/27/2016)... 2016  Global demand for enzymes is forecast ... to $7.2 billion.  This market includes enzymes used ... biofuel production, animal feed, and other markets) and ... Food and beverages will remain the largest market ... of products containing enzymes in developing regions.  These ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created 4Sight ... solutions to the healthcare market. The company's primary focus is on new product ... marketing strategies that are necessary to help companies efficiently bring their products to ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
Breaking Biology Technology:
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
(Date:6/1/2016)... YORK , June 1, 2016 ... Technology in Election Administration and Criminal Identification to Boost ... to a recently released TechSci Research report, " Global ... By Region, Competition Forecast and Opportunities, 2011 - 2021", ... 24.8 billion by 2021, on account of growing security ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
Breaking Biology News(10 mins):